The Origin
The Avicenna Alliance itself has its origins in the Avicenna Roadmap, a 2-year EU funded project, led by DG Connect whose goal was to create a research and technological development Roadmap outlining a strategy for In Silico Clinical Trials (ISCT)
Built into the European Commission’s project requirements was a plan to establish a pre-competitive Association - the Avicenna Alliance - that would represent the needs of the in silico medicine community and provide the Commission and other policy makers with expert advice in this field.
The Avicenna Alliance operating since 2016, now works with academic and industry members to refine and implement this Roadmap and identify policy and regulatory obstacles to the enhancement of in silico medicine.
The Journey
Shortly after its creation the global mission of the Avicenna Alliance became a reality, driven by many US based members, the Avicenna leaders engaged with the European parliament as well as with senators and members of the American congress. With members present in Asia and the Middle East, the organisation engages with authorities around the world and has become an observing member of IMDRF (International Medical Devices Regulators Forum)..
The Future
While many of us are convinced of the importance of in silico methods to revolutionise healthcare, the ultimate mission of the Avicenna Alliance is to ensure that in silico medicine becomes a reality both for regulatory approval and for clinical applications. We are aiming for the Personal Digital Avatar (PDA), a digital twin specific to each of us, permanently connected with us to reduce the emergence of diseases and minimise their impact on our daily lives.
Click here to find out if you could benefit from Membership of the Avicenna Alliance.
